Your browser doesn't support javascript.
loading
The molecular hallmarks of primary and secondary vitreoretinal lymphoma.
Bonzheim, Irina; Sander, Philip; Salmerón-Villalobos, Julia; Süsskind, Daniela; Szurman, Peter; Gekeler, Florian; Spitzer, Martin S; Steinhilber, Julia; Kohler, Esther; Büssgen, Melanie; Schittenhelm, Jens; Salaverria, Itziar; Campo, Elias; Coupland, Sarah E; Quintanilla-Martinez, Leticia; Fend, Falko.
Affiliation
  • Bonzheim I; Department of General and Molecular Pathology and Pathological Anatomy, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Sander P; Department of General and Molecular Pathology and Pathological Anatomy, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Salmerón-Villalobos J; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Süsskind D; Centro de Investigación Biomedica en Red en Oncología (CIBERONC), Madrid, Spain.
  • Szurman P; Centre of Ophthalmology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Gekeler F; Sulzbach Eye Clinic, Knappschaft Hospital Saar, Sulzbach, Germany.
  • Spitzer MS; Centre of Ophthalmology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Steinhilber J; Department of Ophthalmology, Klinikum Stuttgart, Stuttgart, Germany.
  • Kohler E; Clinic for Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Büssgen M; Department of General and Molecular Pathology and Pathological Anatomy, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Schittenhelm J; Department of General and Molecular Pathology and Pathological Anatomy, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Salaverria I; Department of General and Molecular Pathology and Pathological Anatomy, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Campo E; Department of Neuropathology, Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Coupland SE; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Quintanilla-Martinez L; Centro de Investigación Biomedica en Red en Oncología (CIBERONC), Madrid, Spain.
  • Fend F; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Blood Adv ; 6(5): 1598-1607, 2022 03 08.
Article in En | MEDLINE | ID: mdl-34448823
ABSTRACT
Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). The diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Because of its rarity and the difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The purpose of our study was to investigate the mutational profile of a large series of primary and secondary VRL. Targeted next-generation sequencing using a custom panel containing the most frequent mutations in PCNSL was performed on 34 vitrectomy samples from 31 patients with VRL and negative controls with uveitis. In a subset of cases, genome-wide copy number alterations (CNAs) were assessed using the OncoScan platform. Mutations in MYD88 (74%), PIM1 (71%), CD79B (55%), IGLL5 (52%), TBL1XR1 (48%), ETV6 (45%), and 9p21/CDKN2A deletions (75%) were the most common alterations, with similar frequencies in primary (n = 16), synchronous (n = 3), or secondary (n = 12) VRL. This mutational spectrum is similar to MYD88mut/CD79Bmut (MCD or cluster 5) DLBCL with activation of Toll-like and B-cell receptor pathways and CDKN2A loss, confirming their close relationship. OncoScan analysis demonstrated a high number of CNAs (mean 18.6 per case). Negative controls lacked mutations or CNAs. Using cell-free DNA of vitreous fluid supernatant, mutations present in cellular DNA were reliably detected in all cases examined. Mutational analysis is a highly sensitive and specific tool for the diagnosis of VRL and can also be applied successfully to cell-free DNA derived from the vitreous.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uveitis / Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Central Nervous System Neoplasms / Retinal Neoplasms / Cell-Free Nucleic Acids Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uveitis / Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Central Nervous System Neoplasms / Retinal Neoplasms / Cell-Free Nucleic Acids Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Affiliation country: Germany